5年和5年以上延长内分泌方案治疗早期乳腺癌疗效的Meta分析

• 药品评价-循证医学研究 • 上一篇下一篇

5年和5年以上延长内分泌方案治疗早期乳腺癌疗效的Meta分析

韩洪娜,陈永法

中国药科大学国际医药商学院,中国药科大学国际医药商学院

收稿日期:2016-04-12 修回日期:2016-04-18 出版日期:2016-06-25 发布日期:2016-06-25

Five or More Years of Adjuvant Endocrine Therapy in Early Breast Cancer：A Meta-analysis

School of International Pharmaceutical Business, China Pharmaceutical University,

Received:2016-04-12 Revised:2016-04-18 Online:2016-06-25 Published:2016-06-25

摘要/Abstract

摘要： ［摘要］目的：基于国内外临床试验结果，探讨5年和5年以上延长内分泌方案治疗早期乳腺癌疗效的差异。方法：检索国内外数据库，对符合纳入标准的文献进行分析。结果：纳入8篇文献，共23070例患者，主要指标无复发生存（RFS）比较，合并RR值为0.81，95%CI（0.69，0.96），经Z检验，P=0.01，差异有统计学意义；总生存（OS）比较，合并RR值为0.93，95%CI（0.88，0.99），经Z检验，P=0.02，差异有统计学意义；乳腺癌特异性生存（BCSS）比较，合并RR值为0.87，95%CI（0.80，0.95），经Z检验，P=0.002，差异有统计学意义；次要指标无远处复发生存（D-RFS）比较，合并RR值为0.78，95%CI（0.59，1.03），经Z检验，P=0.08，差异无统计学意义；无局部复发生存（LR-RFS）比较，合并RR值为0.72，95%CI（0.58，0.89）经Z检验，P=0.003，差异有统计学意义。结论：5年以上延长内分泌方案治疗早期乳腺癌的疗效优于5年方案。

Abstract: [Abstract]Objective： Based on the results of clinical trials at home and abroad,to explore the difference of the curative effect in 5 years of therapy alone and that of additional years of endocrine therapy in the treatment of early breast cancer. Methods：Search literature domestic and overseas and analyze the included studies. Results： Trials， including 23，070 patients， were identified. Overall， compared with 5 years of endocrine therapy alone， extended endocrine therapy beyond 5 years of tamoxifen significantly improved RFS：RR=0.81，95%CI（0.69，0.96）； P=0.01，OS；RR=0.93， 95%CI（0.88， 0.99）， P=0.02； BCSS：RR=0.87，95%CI（0.80， 0.95）， P=0.002；D-RFS：RR=0.78，95%CI（0.59，1.03），P=0.08； and LR-RFS：RR=0.72，95%CI（0.58，0.89），P=0.003. Conclusion： For the efficacy， additional adjuvant endocrine therapy was superior to 5 years of tamoxifen.

韩洪娜,陈永法. 5年和5年以上延长内分泌方案治疗早期乳腺癌疗效的Meta分析[J]. .

参考文献

[1] Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials [J]. The Lancet, 1998, 351(9114): 1451-1467.
[2] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. The Lancet, 2013, 381(9869): 805-816.
[3] Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial [J]. Journal of the National Cancer Institute, 2001, 93(9): 684-690.
[4] Goss P E, Ingle J N, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17[J]. Journal of the National Cancer Institute, 2005, 97(17): 1262-1271.
[5] Goss P E, Ingle J N, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA. 17[J]. Journal of clinical oncology, 2007, 25(15): 2006-2011.
[6] Mamounas E P, Jeong J H, Wickerham D L, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial[J]. Journal of Clinical Oncology, 2008, 26(12): 1965-1971.
[7] Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a[J]. Journal of the National Cancer Institute, 2007, 99(24): 1845-1853.
[8] Stewart H J, Prescott R J, Forrest A P M. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years[J]. Journal of the National Cancer Institute, 2001, 93(6): 456-462.
[9] Tormey D C, Gray R, Falkson H C, et al. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer[J]. Journal of the National Cancer Institute, 1996, 88(24): 1828-1833.
[10] Gray R G, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[C]//ASCO Annual Meeting Proceedings. 2013, 31(18_suppl): 5.
[11] 韦小芳.内分泌治疗5年后继续强化治疗乳腺癌临床疗效的Meta分析[D].广西医科大学, 2012.